Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.

Suzuki D, Toyoda M, Kimura M, Miyauchi M, Yamamoto N, Sato H, Tanaka E, Kuriyama Y, Miyatake H, Abe M, Umezono T, Fukagawa M

Internal medicine (Tokyo, Japan)15 May 2013Cited by 44 (Europe PMC)

PMID23676586DOI10.2169/internalmedicine.52.8961PepBankPUB-23676586

Source link PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes, preprandial blood glucose at six months of liraglutide was higher than at baseline.
In plain wordsIn Japanese adults with type 2 diabetes, blood sugar before meals was higher at six months than at the start.
Peptide
Liraglutide
Outcome
IncreasePreprandial blood glucose
Study
n = 59
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3 mg/day for at least 1 week, then 0.6 mg/day for at least 1 week, gradually increasing to 0.9 mg/day · six monthsAs given in this study (human).
Measurements
Preprandial blood glucose
148.8 mg/dL
six months
Preprandial blood glucose
130.8 mg/dL
baseline
Source sentences
Summary
At six months after treatment, the preprandial blood glucose levels were higher (148.8±40.5 mg/dL) than the baseline values (130.8±36.7, p<0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 59 patients with type 2 diabetes were treated with liraglutide (0.3 mg/day for ≥1 week and then 0.6 mg/day for ≥1 week, gradually increasing the dose to 0.9 mg/day) for six months.
Report a problemFND-2367658601
02HumanNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes, body weight was lower after six months of liraglutide.
In plain wordsIn Japanese adults with type 2 diabetes, body weight was lower after six months of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n = 59
Outcome group
Body weight · Metabolic and weight
Studied dose
0.3 mg/day for at least 1 week, then 0.6 mg/day for at least 1 week, gradually increasing to 0.9 mg/day · six monthsAs given in this study (human).
Source sentences
Summary
however, body weight, BMI and abdominal circumference were lower, and the liver/kidney CT ratio improved significantly from 1.64±0.44 at baseline to 1.78±0.42.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 59 patients with type 2 diabetes were treated with liraglutide (0.3 mg/day for ≥1 week and then 0.6 mg/day for ≥1 week, gradually increasing the dose to 0.9 mg/day) for six months.
Report a problemFND-2367658602
03HumanNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes, BMI was lower after six months of liraglutide.
In plain wordsIn Japanese adults with type 2 diabetes, BMI was lower after six months of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n = 59
Outcome group
Body weight · Metabolic and weight
Studied dose
0.3 mg/day for at least 1 week, then 0.6 mg/day for at least 1 week, gradually increasing to 0.9 mg/day · six monthsAs given in this study (human).
Source sentences
Summary
however, body weight, BMI and abdominal circumference were lower, and the liver/kidney CT ratio improved significantly from 1.64±0.44 at baseline to 1.78±0.42.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 59 patients with type 2 diabetes were treated with liraglutide (0.3 mg/day for ≥1 week and then 0.6 mg/day for ≥1 week, gradually increasing the dose to 0.9 mg/day) for six months.
Report a problemFND-2367658603
04HumanNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes, abdominal circumference was lower after six months of liraglutide.
In plain wordsIn Japanese adults with type 2 diabetes, waist size was smaller after six months of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseAbdominal circumference
Study
n = 59
Outcome group
Body weight · Metabolic and weight
Studied dose
0.3 mg/day for at least 1 week, then 0.6 mg/day for at least 1 week, gradually increasing to 0.9 mg/day · six monthsAs given in this study (human).
Source sentences
Summary
however, body weight, BMI and abdominal circumference were lower, and the liver/kidney CT ratio improved significantly from 1.64±0.44 at baseline to 1.78±0.42.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 59 patients with type 2 diabetes were treated with liraglutide (0.3 mg/day for ≥1 week and then 0.6 mg/day for ≥1 week, gradually increasing the dose to 0.9 mg/day) for six months.
Report a problemFND-2367658604
05HumanNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes, the liver/kidney CT ratio improved significantly from 1.64 at baseline to 1.78 after six months of liraglutide.
In plain wordsIn Japanese adults with type 2 diabetes, a CT measure of liver fat improved after six months of liraglutide.
Peptide
Liraglutide
Outcome
IncreaseLiver/kidney CT ratio
Study
n = 59
Outcome group
Liver fat and liver function · Liver
Studied dose
0.3 mg/day for at least 1 week, then 0.6 mg/day for at least 1 week, gradually increasing to 0.9 mg/day · six monthsAs given in this study (human).
Measurements
Liver/kidney CT ratio
1.64 ratio
baseline
Liver/kidney CT ratio
1.78 ratio
six months
Source sentences
Summary
the liver/kidney CT ratio improved significantly from 1.64±0.44 at baseline to 1.78±0.42.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 59 patients with type 2 diabetes were treated with liraglutide (0.3 mg/day for ≥1 week and then 0.6 mg/day for ≥1 week, gradually increasing the dose to 0.9 mg/day) for six months.
Report a problemFND-2367658605
06HumanNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes not pretreated with insulin resistance ameliorators, liraglutide significantly decreased subcutaneous fat areas.
In plain wordsIn Japanese adults with type 2 diabetes, liraglutide reduced the area of fat under the skin.
Peptide
Liraglutide
Outcome
DecreaseSubcutaneous fat area
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
0.3 mg/day for at least 1 week, then 0.6 mg/day for at least 1 week, gradually increasing to 0.9 mg/day · six monthsAs given in this study (human).
Source sentences
Summary
An analysis of the patients who were not pretreated with insulin resistance ameliorators showed that six months of liraglutide treatment significantly decreased the subcutaneous
2 context sentences(design, population, supporting numbers)
Summary · context
An analysis of the patients who were not pretreated with insulin resistance ameliorators
Summary · context
A total of 59 patients with type 2 diabetes were treated with liraglutide (0.3 mg/day for ≥1 week and then 0.6 mg/day for ≥1 week, gradually increasing the dose to 0.9 mg/day) for six months.
Report a problemFND-2367658606
07HumanNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes not pretreated with insulin resistance ameliorators, liraglutide did not significantly change visceral fat areas.
In plain wordsIn Japanese adults with type 2 diabetes, liraglutide did not significantly change the area of fat around the organs.
Peptide
Liraglutide
Outcome
No significant changeVisceral fat area
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
0.3 mg/day for at least 1 week, then 0.6 mg/day for at least 1 week, gradually increasing to 0.9 mg/day · six monthsAs given in this study (human).
Source sentences
Summary
An analysis of the patients who were not pretreated with insulin resistance ameliorators showed that six months of liraglutide treatment significantly decreased the subcutaneous but not visceral fat areas, significantly decreased the serum adiponectin levels and significantly increased the serum PTX3 levels.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 59 patients with type 2 diabetes were treated with liraglutide (0.3 mg/day for ≥1 week and then 0.6 mg/day for ≥1 week, gradually increasing the dose to 0.9 mg/day) for six months.
Report a problemFND-2367658607
08HumanNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes not pretreated with insulin resistance ameliorators, liraglutide significantly decreased serum adiponectin levels.
In plain wordsIn Japanese adults with type 2 diabetes, serum adiponectin was lower after six months of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseSerum adiponectin
Study
n: not reported in source
Outcome group
Inflammation markers · Metabolic and weight
Studied dose
0.3 mg/day for at least 1 week, then 0.6 mg/day for at least 1 week, gradually increasing to 0.9 mg/day · six monthsAs given in this study (human).
Source sentences
Summary
An analysis of the patients who were not pretreated with insulin resistance ameliorators showed that six months of liraglutide treatment significantly decreased the subcutaneous but not visceral fat areas, significantly decreased the serum adiponectin levels and significantly increased the serum PTX3 levels.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 59 patients with type 2 diabetes were treated with liraglutide (0.3 mg/day for ≥1 week and then 0.6 mg/day for ≥1 week, gradually increasing the dose to 0.9 mg/day) for six months.
Report a problemFND-2367658608
09HumanNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes not pretreated with insulin resistance ameliorators, liraglutide significantly increased serum PTX3 levels.
In plain wordsIn Japanese adults with type 2 diabetes, serum PTX3 was higher after six months of liraglutide.
Peptide
Liraglutide
Outcome
IncreaseSerum pentraxin 3 (PTX3)
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
0.3 mg/day for at least 1 week, then 0.6 mg/day for at least 1 week, gradually increasing to 0.9 mg/day · six monthsAs given in this study (human).
Source sentences
Summary
An analysis of the patients who were not pretreated with insulin resistance ameliorators showed that six months of liraglutide treatment significantly decreased the subcutaneous but not visceral fat areas, significantly decreased the serum adiponectin levels and significantly increased the serum PTX3 levels.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 59 patients with type 2 diabetes were treated with liraglutide (0.3 mg/day for ≥1 week and then 0.6 mg/day for ≥1 week, gradually increasing the dose to 0.9 mg/day) for six months.
Report a problemFND-2367658609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.

Summary

Results from this study9

Version history

Subjects

Publication types

MeSH terms